Search - tctmd.com

Displaying 241 - 260 of 330

Sort: Relevancy | Date

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

News Conference News WCC 2018

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

December 06, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

November 30, 2018

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

November 23, 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

October 02, 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

August 15, 2018

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

July 02, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.